-
Cytokine Market Is Booming Worldwide 2024-2031 | Biocon Limited, Johnson & Johnson, Abbvie Inc.
22 Mar 2024 06:22 GMT
… companies in Cytokine Market are: Biocon Limited, Johnson & Johnson, Abbvie … Cytokine Types
By Therapeutic Application: Cancer, Asthma and Airway Inflammation, Arthritis …
-
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
29 Feb 2024 15:22 GMT
… their respective owners.
About Biocon Biologics Limited: Biocon Biologics Ltd. (BBL), a … Twitter: @BioconBiologics for company updates.
Biocon Limited, publicly listed in 2004 … for chronic conditions like diabetes, cancer and autoimmune. It has developed …
-
Cancer drugmaker Bristol Myers to build its largest R&D facility outside US in India by 2025
27 Feb 2024 08:54 GMT
… with the Biocon Group's Syngene International.
The cancer-focused U … is yet to launch its cancer cell therapies Abecma and … country, but its other cancer drugs such as nivolumab and … as blood thinner Eliquis and cancer immunotherapy Opdivo to lose patent …
-
Biocon Biologics focusing on market share gains of biosimilars in key markets
13 Feb 2024 10:56 GMT
… the operating margins of Biocon Biologics. The company … requirements in certain countries, Biocon Biologics has completed the … contribute about 75% of Biocon Biologics revenue, while the … has licensed biosimilars against cancers trastuzumab and bevacizumab in …
-
FY25 to be year of consolidation for Biocon Biologics: CEO Tambe
10 Feb 2024 02:19 GMT
… the acquisition is seen, Biocon’s biosimilar business managed … to treat early-stage breast cancer, had a market share … Thursday, it’s parent Biocon posted a revenue from operations … non-core business assets – Biocon Biologics’ Dermatology and Nephrology branded …
-
Biocon Biologics partners with Sandoz Australia for cancer biosimilars
09 Feb 2024 20:35 GMT
… biosimilars company and subsidiary of Biocon, has announced a five-year … agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI (bTrastuzumab … various cancers.
Matt Erick, Chief Commercial Officer of Advanced Markets, Biocon Biologics …
-
Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia
09 Feb 2024 11:22 GMT
… and distribution of two cancer treatment biosimilar products in … and Bevacizumab in Australia, Biocon Biologics said in a … agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri … Officer - Advanced Markets at Biocon Biologics, said.
This …
-
Biocon Biologics, Sandoz Australia ink pact for biosimilars Trastuzumab, Bevacizumab
09 Feb 2024 08:53 GMT
… , Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab … the treatment of various cancers.
The agreement is effective … Officer of Advanced Markets, Biocon Biologics Ltd, said, … injection Adalimumab in Japan
Biocon Biologics Ltd. (BBL), …
-
World News | Biocon Biologics Inks Pact with Sandoz for Sale of 2 Biosimilar Products in Australia
09 Feb 2024 06:09 GMT
… and distribution of two cancer treatment biosimilar products in … and Bevacizumab in Australia, Biocon Biologics said in a … agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri … Officer - Advanced Markets at Biocon Biologics, said.
This …
-
Biocon Biologics Partners With Sandoz Australia For Biosimilars Trastuzumab And Bevacizuma
09 Feb 2024 05:24 GMT
… Trastuzumab And Bevacizuma | Image: Biocon (Representative)
Biocon Biologics Ltd (BBL), a fully … agreement, Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and … for the treatment of various cancers.
The agreement is effective from …